Chong Kun Dang announced on the 12th that Lucentis’ biosimilar CKD-701 proved equivalent to the original drug in Phase 3 trials. Chong Kun Dang will apply to the MFDS for CKD-701. Lucentis, sold by Roche and Novatis, is a drug used to treat eye diseases such as wet age-related macular degeneration (AMD) and diabetic retinopathy. Lucentis' annual global sales amount to about ₩4.6 trillion.

From September 2018 to March this year, Chong Kun Dang conducted clinical trials for the first purpose of proving the validity of CKD-701 and Lucentis in patients with wet macular degeneration. Clinical trials showed that the proportion of patients with vision loss of less than 15 characters at BCVA at 3 months'